More recently, biological therapy has become a promising option in the treatment of HS, with adalimumab (a TNF-α inhibitor), secukinumab (an IL-17A inhibitor) and bimekizumab (an IL-17A and −17F inhibitor) now approved for the treatment of HS. This evidence concerns the gene IL17A and histiocytic sarcoma.